李明川，廣州醫(yī)科大學(xué)附屬腫瘤醫(yī)院腫瘤研究所，教授，碩士生導(dǎo)師

基本情況簡(jiǎn)介：

博士，廣州醫(yī)科大學(xué)“南山學(xué)者”骨干人才。主要研究方向?yàn)榱字x在癌癥、抗癌藥物心肌毒性中的作用和分子機(jī)制。近年在Circulation、Cardiovascular Research、Science Translational Medicine等期刊累計(jì)發(fā)表研究論文20余篇。主持國(guó)家自然科學(xué)基金青年基金項(xiàng)目，廣東省基礎(chǔ)與應(yīng)用基礎(chǔ)研究基金項(xiàng)目等。擔(dān)任中國(guó)生物化學(xué)與分子生物學(xué)會(huì)脂質(zhì)與脂蛋白專業(yè)分會(huì)青年委員；《解放軍醫(yī)學(xué)》雜志青年編委；Cardiovascular Research、Oxidative Medicine and Cellular Longevity等雜志審稿人。

聯(lián)系方式:[email protected]

研究領(lǐng)域

磷脂代謝與細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)

科研項(xiàng)目

1. 廣州醫(yī)科大學(xué)“南山學(xué)者”骨干人才配套經(jīng)費(fèi)，2023.03-2028.03，300萬(wàn)，主持

2. 國(guó)家自然科學(xué)基金青年基金項(xiàng)目，2021.01-2023.12，24萬(wàn)，主持

3. 廣東省基礎(chǔ)與應(yīng)用基礎(chǔ)研究基金聯(lián)合基金青年基金項(xiàng)目，2020.01-2022.12，9萬(wàn)，主持

代表性論著（*第一作者，#通訊作者）

1. Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, Di Bona A, et al. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation. 2018, 138(7):696-711. (IF: 37.8)

2. Huang J, Wu R, Chen L, Yang Z, Yan D^#, Li M^#. Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect. Frontiers in Pharmacology. 2022, 13: 811406. #Corresponding Authors (IF: 5.810)

3. Zhu B, Zhong W, Cao X, Pan G, Xu M, Zheng J, Chen H, Feng X, Luo C, Lu C, Xiao J, Lin W, Lai C, Li M, Du X, Yi Q, Yan D. Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice. Science Translational Medicine. 2022, 14(629):eabh2548. (IF: 17.956)

4. Zhong W, Cao X, Pan G, Niu Q, Feng X, Xu M, Li M, Huang Y, Yi Q, Yan D. ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1. Blood. 2022, 139(7):1052-1065. (IF: 22.113)

5. Li M, Russo M, Pirozzi F, Tocchetti CG, Ghigo A. Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities. BBA-Molecular Cell Research. 2020, 1867(3):118493. (IF: 4.739)

6. Russo M, Guida F, Paparo L, Trinchese G, Aitoro R, Avagliano C, Fiordelisi A, Napolitano F, Mercurio V, Sala V, Li M, Sorriento D, Ciccarelli M, Ghigo A, Hirsch E, Bianco R, Iaccarino G, Abete P, Bonaduce D, Calignano A, Berni Canani R, Tocchetti CG. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity. European Journal of Heart Failure. 2019, 21(4):519-528. (IF：13.965)

7. Ghigo A, Laffargue M, Li M, Hirsch E. PI3K and Calcium Signaling in Cardiovascular Disease. Circulation Research. 2017, 121(3):282-292. (IF: 15.862)

8. Li M*, Murabito A*, Ghigo A, Hirsch E. PI3Ks in Diabetic Cardiomyopathy. Journal of Cardiovascular Pharmacology. 2017, 70(6):422-429. *equal contributors (IF: 2.371)

9. Ghigo A*, Li M*, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. BBA-Molecular Cell Research. 2016, 1863(7):1916-25. *equal contributors (IF: 4.739)

10. Li M, Hirsch E. Akt activation by PHLPP1 ablation prevents pathological hypertrophy by promoting angiogenesis. Cardiovascular Research. 2015, 105:129–130. (IF: 10.787)

11. Ghigo A, Li M. Phosphoinositide 3-kinase: Friend and foe in cardiovascular disease. Frontiers in Pharmacology. 2015, 6:169. (IF：3.845)

12. Li M-C*, Liu Q-Q*, Zhang Y-L, Wang L-L, Lu X-Y. Heterologous expression of human costimulatory molecule B7-2 and construction of B7-2 Immobilized PHA nanoparticles as immune activation agent. BMC Biotechnology. 2012, 12:43. *equal contributors (IF: 2.303)